Ganesh; Thota

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ganesh; Thota.The latest application filed is for "bis-biguanide compounds, pharmaceutical compositions and uses in managing cancer".

Company Profile

2.13.17

Ganesh; Thota - Alpharetta GA
GANESH; Thota - Atlanta GA
Ganesh; Thota - Blacksburg VA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Bis-Biguanide Compounds, Pharmaceutical Compositions and Uses in Managing Cancer App 20220168244 - Marcus; Adam ; et al.	2022-06-02
Prostaglandin Receptor Ep2 Antagonists, Derivatives, And Uses Related Thereto App 20220162186 - GANESH; Thota ; et al.	2022-05-26
Prostaglandin Receptor Ep2 Antagonists, Derivatives, Compositions, And Uses Related Thereto App 20220000883 - Ganesh; Thota ; et al.	2022-01-06
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto Grant 11,077,120 - Ganesh , et al. August 3, 2	2021-08-03
Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto App 20200085837 - Ganesh; Thota ; et al.	2020-03-19
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto Grant 10,568,889 - Ganesh , et al. Feb	2020-02-25
Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto App 20180318315 - Ganesh; Thota ; et al.	2018-11-08
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto Grant 10,052,332 - Ganesh , et al. August 21, 2	2018-08-21
Quinazoline derivatives, compositions, and uses related thereto Grant 10,045,989 - Lambeth , et al. August 14, 2	2018-08-14
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto Grant 10,040,783 - Jiang , et al. August 7, 2	2018-08-07
Quinazoline compounds and their use in therapy Grant 9,932,317 - Brown , et al. April 3, 2	2018-04-03
Quinazoline derivatives, compositions, and uses related thereto Grant 9,868,728 - Lambeth , et al. January 16, 2	2018-01-16
Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto App 20170081314 - Jiang; Jianxiong ; et al.	2017-03-23
Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto App 20170042905 - Ganesh; Thota ; et al.	2017-02-16
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto Grant 9,518,044 - Jiang , et al. December 13, 2	2016-12-13
Piperazine derivatives, compositions, and uses related thereto Grant 9,428,478 - Ganesh , et al. August 30, 2	2016-08-30
Quinazoline Derivatives, Compositions, and Uses Related Thereto App 20160243121 - Lambeth; John David ; et al.	2016-08-25
Quinazoline Derivatives, Compositions, And Uses Related Thereto App 20150110723 - Lambeth; John David ; et al.	2015-04-23
Quinazoline Compounds And Their Use In Therapy App 20150057263 - Brown; Robert ; et al.	2015-02-26
Piperazine Derivatives, Compositions, And Uses Related Thereto App 20140194422 - Ganesh; Thota ; et al.	2014-07-10
Prostaglandin Receptor Ep2 Antagonists, Derivatives, Compositions, And Uses Related Thereto App 20140179750 - Jiang; Jianxiong ; et al.	2014-06-26
Quinazoline Derivatives, Compositions, And Uses Related Thereto App 20130225612 - Lambeth; John David ; et al.	2013-08-29
Conformationally constrained paclitaxel analogs and their use as anticancer and anti-Alzheimers agents Grant 7,312,240 - Kingston , et al. December 25, 2	2007-12-25
Conformationally constrained paclitaxel analogs and their use as anticancer and anti-alzheimers agents App 20050187287 - Ian Kingston, David George ; et al.	2005-08-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.